Xingkang S. Jiang
Tianjin, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 28 publications
Smarter, Not More: The Rationale for Reducing Systematic Cores in the MRI-Targeted Biopsy Era.
Journal: The Canadian journal of urology
Published: May 25, 2026
Irreversible electroporation in prostate cancer: efficacy, tumor immune microenvironment remodeling, and combination immunotherapy-a narrative review.
Journal: Translational andrology and urology
Published: November 18, 2025
Correction: Comparing Regional Saturation Biopsy and Targeted Biopsy: Is Perilesional Biopsy Necessary for High-Prostate-Specific Antigen Patients?
Journal: Annals of surgical oncology
Published: August 12, 2025
Comparing Regional Saturation Biopsy and Targeted Biopsy: Is Perilesional Biopsy Necessary for High-Prostate-Specific Antigen Patients?
Journal: Annals of surgical oncology
Published: May 19, 2025
Targeted and perilesional biopsy: triumphs and cautions.
Journal: Prostate cancer and prostatic diseases
Published: December 30, 2024
Personalized prostate biopsy protocols: enhancing cancer detection through tailored approaches-a narrative review.
Journal: Translational andrology and urology
Published: October 30, 2024
Development and validation of multivariable biopsy-free nomograms to predict clinically significant prostate cancer in patients with prostate-specific antigen levels ≥20 ng/mL.
Journal: Translational andrology and urology
Published: September 28, 2024
Development and validation of biopsy free nomograms for predicting clinically significant prostate cancer in men with PI-RADS 4 and 5 lesions.
Journal: Scientific reports
Published: July 06, 2024
Comparison of induction protocols for VEN+AZA and HAG+AZA in single-center elderly acute myeloid leukemia
Journal: Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
Published: December 04, 2023
Comparison of Regional Saturation Biopsy, Targeted Biopsy, and Systematic Biopsy in Patients with Prostate-specific Antigen Levels of 4-20 ng/ml: A Prospective, Single-center, Randomized Controlled Trial.
Journal: European urology oncology
Published: November 13, 2023
Exosomal lincROR Promotes Docetaxel Resistance in Prostate Cancer through a β-catenin/HIF1α Positive Feedback Loop.
Journal: Molecular cancer research : MCR
Published: June 09, 2022
TFAP2C-Mediated lncRNA PCAT1 Inhibits Ferroptosis in Docetaxel-Resistant Prostate Cancer Through c-Myc/miR-25-3p/SLC7A11 Signaling.
Journal: Frontiers in oncology
Published: January 25, 2022
Last Updated: 09/26/2026